BioLife Solutions, Inc. (BLFS) EPS Estimated At $-0.07; Profile of 4 Analysts Covering Immune Pharmaceuticals Inc. (IMNP)

February 14, 2018 - By Ellis Scott

Analysts expect BioLife Solutions, Inc. (NASDAQ:BLFS) to report $-0.07 EPS on March, 8.They anticipate $0.03 EPS change or 75.00% from last quarter’s $-0.04 EPS. After having $-0.03 EPS previously, BioLife Solutions, Inc.’s analysts see 133.33% EPS growth. The stock increased 3.23% or $0.17 during the last trading session, reaching $5.4. About 17,752 shares traded. BioLife Solutions, Inc. (NASDAQ:BLFS) has risen 37.27% since February 14, 2017 and is uptrending. It has outperformed by 20.57% the S&P500.

Among 4 analysts covering Immune Pharma (NASDAQ:IMNP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immune Pharma had 4 analyst reports since October 8, 2015 according to SRatingsIntel. The rating was initiated by TH Capital with “Buy” on Thursday, October 8. The stock has “Buy” rating by Chardan Capital Markets on Tuesday, October 13. The rating was initiated by Roth Capital on Thursday, October 8 with “Buy”. See Immune Pharmaceuticals Inc. (NASDAQ:IMNP) latest ratings:

05/01/2018 Broker: Maxim Group Rating: Buy New Target: $3.0

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. The company has market cap of $75.70 million. The Company’s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. It currently has negative earnings. The firm offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing.

Investors sentiment increased to 8 in 2017 Q3. Its up 6.00, from 2 in 2017Q2. It improved, as 2 investors sold BioLife Solutions, Inc. shares while 0 reduced holdings. 11 funds opened positions while 5 raised stakes. 1.98 million shares or 721.11% more from 241,668 shares in 2017Q2 were reported. Price T Rowe Assocs Md owns 16,900 shares for 0% of their portfolio. Manatuck Hill Prtnrs Limited Liability Co stated it has 0.14% in BioLife Solutions, Inc. (NASDAQ:BLFS). Renaissance Techs Limited Liability invested in 0% or 86,900 shares. Thompson Davis & owns 250 shares. Community Savings Bank Na reported 250 shares. Vanguard stated it has 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Essex Invest Mgmt Ltd Com has invested 0.07% in BioLife Solutions, Inc. (NASDAQ:BLFS). Perkins has 15,000 shares for 0.09% of their portfolio. Virtu Fincl Ltd Limited Liability Company invested in 16,793 shares. Janney Montgomery Scott Ltd Limited Liability Company holds 0% of its portfolio in BioLife Solutions, Inc. (NASDAQ:BLFS) for 14,600 shares. Pnc Financial Serv Grp stated it has 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Hudock Capital Gp Lc invested 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Eam Ltd Limited Liability Company reported 97,077 shares. Moreover, Granite Prns Limited Liability Company has 0.07% invested in BioLife Solutions, Inc. (NASDAQ:BLFS) for 211,030 shares. Geode Cap Mgmt Limited Co stated it has 0% in BioLife Solutions, Inc. (NASDAQ:BLFS).

Since January 16, 2018, it had 0 insider purchases, and 1 sale for $69,848 activity. $69,848 worth of stock was sold by Rice Michael on Tuesday, January 16.

Among 2 analysts covering BioLife Solutions (NASDAQ:BLFS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLife Solutions had 6 analyst reports since June 14, 2017 according to SRatingsIntel. Maxim Group upgraded the shares of BLFS in report on Thursday, November 30 to “Buy” rating. The rating was upgraded by Janney Capital to “Buy” on Wednesday, July 5. The rating was maintained by Maxim Group with “Buy” on Friday, August 11. The stock has “Buy” rating by Maxim Group on Wednesday, June 14. On Friday, November 10 the stock rating was maintained by Maxim Group with “Buy”. Maxim Group maintained the stock with “Buy” rating in Monday, July 31 report.

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company has market cap of $8.65 million. The companyÂ’s lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohnÂ’s, and ulcerative colitis diseases. It currently has negative earnings. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>